TearLab Announces Fourth Quarter 2015 Preliminary Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TearLab Announces Fourth Quarter 2015 Preliminary Financial Estimates and Provides Corporate Update

SAN DIEGO, Feb. 01, 2016 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ: TEAR ) (TSX: TLB ) (“TearLab” or “the Company”) announced today certain preliminarily unaudited financial estimates for the fourth quarter of 2015 and provided an update on its business.

Preliminary Unaudited Q4-2015 Revenue and Available Cash

TearLab estimates that total revenue for the quarter ended December 31, 2015 will be approximately $6.8 million, reflecting an increase of approximately 28% from the fourth quarter of 2014.  In addition, TearLab estimates that a net total of 258 TearLab Osomarlity® Systems were added in the fourth quarter of 2015, of which 200 were under the Company’s new Flex program and 66 were purchased outside of the United States.

The following table sets out the estimated annualized revenue per U.S. device and account analysis for the fourth quarter ended December 31, 2015:

Program Active Devices Active Accounts Annualized Revenues Per Device Annualized Revenues Per Account
Purchased 277 231   $   1,780   $    2,134  
Use 391 390   $   7,408   $   7,427  
Masters 1,708 234   $   4,330   $   31,605  
Flex 1,550 700   $   8,409   $   18,621  
Total: 3,926 1,555      
           

“Our fourth quarter revenue growth reflects the continued adoption of TearLab’s osmolarity test along with solid sales execution in adding nearly 100 new Flex customers,” commented Seph Jensen, TearLab’s Chief Executive Officer.

For the full year 2015, the Company anticipates total revenue to be approximately $25.2 million, representing total year-over-year revenue growth of approximately 28%.  In addition, the Company estimates its available cash balance at December 31, 2015 to be $13.8 million.

These figures are preliminary and unaudited, and actual results may differ. The Company currently expects to report audited full year financial results in March 2016.

Next Generation Tear Testing Platform

TearLab continues to make progress toward introducing its next product, a multiplex testing platform that combines the measurement of osmolarity and other biomarkers in human tears in a single test.   The Company has recently completed the development of an alpha device and is planning to initiate the necessary clinical studies for obtaining regulatory approvals in the coming months. 

“We believe our next generation platform will bring significant value to clinicians by providing previously unavailable molecular data that will guide more targeted treatment decisions,” said Dr. Benjamin Sullivan, TearLab’s Chief Scientific Officer.  “Based on market research and feedback from key opinion leaders, we are initially pursuing a test which includes both osmolarity and inflammatory biomarkers.  Also, we believe the new platform will enable future expansion into testing for a range of eye diseases.”

TearLab currently expects to launch its new multiplex testing platform, subject to regulatory approval, in Europe and the United States in mid-2016 and 2017, respectively.  

OcuHub Update

TearLab also announced that, based on a strategic review of its business, it has made a decision to initiate a divestiture or orderly wind down of its majority owned OcuHub, LLC (“OcuHub”) subsidiary.  

While TearLab continues to explore a possible sale of OcuHub, if a divestiture transaction does not materialize, the wind down of the OcuHub operations is expected to be completed by the end of the first quarter of 2016.  TearLab expects to record a pre-tax charge of approximately $1.4 million related to the impairment of intangibles and fixed assets, which will be recorded in the fourth quarter of 2015.  In addition, in the event of a wind down of the OcuHub business, TearLab expects to record an estimated pre-tax restructuring charge of approximately $0.6 million for expenses related to winding down the business in the first quarter of 2016.  However, the final restructuring charge and actual cost of winding down the business may vary significantly depending on the final disposition of OcuHub.

"Following on the heels of strong growth throughout 2015, we concluded that focusing all of our resources on the core diagnostics business is the best way to achieve our goal of maximizing value for our shareholders," said Mr. Jensen.  OcuHub’s 2015 estimated operating expenses, excluding the impairment charge, were approximately $3.5 million.  TearLab expects to see a favorable impact of $3.5 million on its operating expenses on a full year basis after excluding the potential shutdown cost and related first quarter 2016 operating expenses of OcuHub.   

Current Business Outlook

TearLab anticipates that it will maintain a 20 plus percent year-over-year revenue growth rate in 2016.  This may be positively impacted by a number of potential growth accelerators, such as a regulatory approval(s) and commercial launch for TearLab’s next generation multiplex tear testing platform, increased international market development, and the addition of osmolarity testing to professional clinical practice guidelines and protocols, some of which may occur during 2016.  Over the longer-term, the productivity of its installed base should help the gross margins for the osmolarity testing business increase from the approximate 50% level achieved today to up to 60%.  TearLab believes the combination of revenue growth, improving gross margins and disciplined cost control would allow it to achieve positive cash flow from operations when its annual revenue reaches a range of $50 million to $60 million.    

Mr. Jensen concluded, “We are excited about the momentum we have built in 2015, and now with the focus solely on our diagnostics platform, we believe we are in a great position to expand adoption going forward.”    

About TearLab Corporation

TearLab Corporation ( www.tearlab.com ) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care.  The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

In order to provide TearLab’s investors with an understanding of our current intentions and future prospects, this release may contain statements that are forward-looking.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding the value proposition of our next generation platform, the timing of its launch, the OcuHub divestiture’s impact on expenses, and the business outlook. 

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including market risk and the risks we identify in reports filed with the SEC.

Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the SEC. TearLab does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof except as required by law. 

CONTACT: CONTACTS: Investors: Stephen Kilmer (647) 872-4849 skilmer@tearlab.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 255

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 339

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 215

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 169

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 266

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 209

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 156

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 232

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Runway Growth Finance Highlights Portfolio Performance 2025

Updated Category News Views 258

Overview of Runway Growth Finance Corp. Runway Growth Finance Corp. (NASDAQ: RWAY) is paving its path as a leading provider of flexible capital solutions aimed at late- and growth-stage companies. Their mission is to present an alternative for businesses looking to raise equity, and they have recently shared their quarterly operational update for the period ending June...

Continue Reading
Market Anticipation: Fed's Expected Interest Rate Moves

Updated Category News Views 113

Federal Reserve's Interest Rate Decisions in Focus The upcoming meeting of the Federal Reserve is drawing considerable interest from economists and investors. Everyone is keenly awaiting the outcome regarding potential interest rate cuts as market conditions continue to shift. With the discussion around monetary policy heating up, there’s a range of opinions on how...

Continue Reading
Argon Medical Makes Progress with Innovative PE Treatment Trial

Updated Category News Views 361

Argon Medical Devices Launches CLEAN-PE Study for Pulmonary Embolism Argon Medical Devices is making significant strides in the medical field with its recent announcement of the first patient enrollment in the CLEAN-PE study. This prospective and multicenter study is designed to test the Cleaner™ Pro Thrombectomy System, which aims to effectively address pulmonary...

Continue Reading
Citi Adjusts PBF Energy Stock Target as Market Challenges Emerge

Updated Category News Views 53

Citi Revises Price Target for PBF Energy Recently, Citi has made a noteworthy adjustment to the price target for PBF Energy (NYSE: PBF), reducing it from $48.00 to $37.00. This update follows an extensive review of the refining company's financial model against the backdrop of fluctuating commodity prices. Despite this shift, Citi maintains a Neutral rating on the stock,...

Continue Reading
Clip Total 3: Revolutionizing Mobile Payments for Businesses

Updated Category News Views 174

Introducing Clip Total 3: A Game-Changer for Businesses Clip, the prominent digital commerce platform in Mexico, has recently launched the Clip Total 3, marking a significant leap in mobile point-of-sale technology for businesses across various sectors. This next-generation device is designed not only for payment acceptance but also for comprehensive business management....

Continue Reading